Piramal Pharma Ltd.
PPLPHARMAHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
14 transcript(s)/analyst meet(s) served; 10 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 14 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20221111 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230213 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230518 | 2023-03-31 | yes | |
| COVER_LETTER | 20230529 | 2023-03-31 | no | |
| TRANSCRIPT | 20230807 | 2023-06-30 | yes | |
| COVER_LETTER | 20231031 | 2023-09-30 | no | |
| COVER_LETTER | 20240202 | 2023-12-31 | no | |
| COVER_LETTER | 20240514 | 2024-03-31 | no | |
| COVER_LETTER | 20240729 | 2024-06-30 | no | |
| COVER_LETTER | 20241026 | 2024-09-30 | no | |
| COVER_LETTER | 20250130 | 2024-12-31 | no | |
| COVER_LETTER | 20251107 | 2025-09-30 | no | |
| COVER_LETTER | 20260130 | 2025-12-31 | no | |
| COVER_LETTER | 20260731 | 2026-06-30 | no |
PPLPHARMA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 208.12 |
| 52-week range | 133.27 – 226.62 |
| Return 1M | 0.2% |
| Return 3M | 24.11% |
| Return 1Y | 6.0% |
| Return 3Y | 114.56% |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 2,270.00 |
| Other income | 89.00 |
| Total income | 2,359.00 |
| Cost of materials consumed | 725.00 |
| Purchases of stock-in-trade | 420.00 |
| Changes in inventories | -293.00 |
| Employee benefit expense | 676.00 |
| Finance costs | 88.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.35 | -0.00 |
| institutions foreign | 0.13 | -0.18 |
| institutions domestic | 0.15 | -0.01 |
| mutual funds | 0.13 | -0.01 |
| public | 0.65 | -0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2026-06-30 | 10 |
| TRANSCRIPT | 2023-06-30 | 4 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,720.00 | 1,716.00 | 2,164.00 | 1,749.00 | 1,911.00 | 1,959.00 | 2,552.00 | 1,951.00 | 2,242.00 | 2,204.00 | 2,754.00 | 1,934.00 | 2,044.00 | 2,140.00 | 2,752.00 | 2,270.00 |
| Other income | 46.00 | 83.00 | 24.00 | 38.00 | 49.00 | 62.00 | 26.00 | 20.00 | 61.00 | 12.00 | 42.00 | 58.00 | 66.00 | 43.00 | 46.00 | 89.00 |
| Total income | 1,766.00 | 1,799.00 | 2,188.00 | 1,787.00 | 1,961.00 | 2,020.00 | 2,579.00 | 1,971.00 | 2,303.00 | 2,216.00 | 2,796.00 | 1,992.00 | 2,109.00 | 2,183.00 | 2,798.00 | 2,359.00 |
| Cost of materials consumed | 434.00 | 350.00 | 487.00 | 417.00 | 532.00 | 628.00 | 400.00 | 471.00 | 575.00 | 805.00 | 204.00 | 524.00 | 483.00 | 505.00 | 483.00 | 725.00 |
| Purchases of stock-in-trade | 222.00 | 332.00 | 202.00 | 268.00 | 244.00 | 228.00 | 436.00 | 315.00 | 395.00 | 161.00 | 547.00 | 343.00 | 375.00 | 377.00 | 336.00 | 420.00 |
| Changes in inventories | 8.00 | -56.00 | 151.00 | -59.00 | -138.00 | -180.00 | 178.00 | -112.00 | -173.00 | -161.00 | 205.00 | -173.00 | -156.00 | -96.00 | 237.00 | -293.00 |
| Employee benefit expense | 470.00 | 492.00 | 474.00 | 496.00 | 516.00 | 524.00 | 494.00 | 580.00 | 560.00 | 556.00 | 612.00 | 619.00 | 611.00 | 600.00 | 586.00 | 676.00 |
| Finance costs | 83.00 | 95.00 | 104.00 | 119.00 | 110.00 | 106.00 | 114.00 | 107.00 | 108.00 | 103.00 | 104.00 | 86.00 | 82.00 | 89.00 | 83.00 | 88.00 |
| Depreciation and amortisation | 166.00 | 164.00 | 184.00 | 174.00 | 185.00 | 186.00 | 196.00 | 185.00 | 192.00 | 197.00 | 243.00 | 197.00 | 203.00 | 213.00 | 218.00 | 224.00 |
| Other expenses | 413.00 | 511.00 | 499.00 | 494.00 | 492.00 | 491.00 | 514.00 | 493.00 | 544.00 | 504.00 | 626.00 | 514.00 | 571.00 | 558.00 | 650.00 | 547.00 |
| Total expenses | 1,797.00 | 1,888.00 | 2,101.00 | 1,909.00 | 1,940.00 | 1,982.00 | 2,333.00 | 2,038.00 | 2,200.00 | 2,167.00 | 2,540.00 | 2,110.00 | 2,170.00 | 2,246.00 | 2,593.00 | 2,386.00 |
| Profit before exceptional items and tax | -30.00 | -89.00 | 87.00 | -121.00 | 20.00 | 38.00 | 246.00 | -67.00 | 103.00 | 50.00 | 257.00 | -118.00 | -61.00 | -63.00 | 205.00 | -27.00 |
| Exceptional items | -7.00 | 0.00 | 0.00 | 0.00 | 0.00 | -32.00 | -31.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00 | 0.00 | -41.00 | -176.00 | 0.00 |
| Profit before tax | -37.00 | -89.00 | 87.00 | -121.00 | 20.00 | 5.00 | 215.00 | -67.00 | 103.00 | 50.00 | 257.00 | -98.00 | -61.00 | -104.00 | 29.00 | -27.00 |
| Current tax | 31.00 | 26.00 | 33.00 | 25.00 | 26.00 | 33.00 | 101.00 | 50.00 | 94.00 | 72.00 | 94.00 | 34.00 | 55.00 | 47.00 | 26.00 | 65.00 |
| Deferred tax | -20.00 | -10.00 | 12.00 | -33.00 | 8.00 | -24.00 | 25.00 | -6.00 | 3.00 | -9.00 | 25.00 | -32.00 | -2.00 | -5.00 | 26.00 | -3.00 |
| Tax expense | 11.00 | 17.00 | 45.00 | -9.00 | 35.00 | 9.00 | 126.00 | 44.00 | 98.00 | 63.00 | 119.00 | 3.00 | 53.00 | 42.00 | 52.00 | 62.00 |
| Profit for the period | -37.00 | -90.00 | 50.00 | -99.00 | 5.00 | 10.00 | 101.00 | -89.00 | 23.00 | 4.00 | 154.00 | -82.00 | -99.00 | -136.00 | -9.00 | -69.00 |
| Profit attributable to owners | — | — | — | — | — | — | — | -89.00 | 23.00 | 4.00 | 154.00 | -82.00 | -99.00 | -136.00 | -9.00 | -69.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 12.00 | 125.00 | 17.00 | 27.00 | 8.00 | 44.00 | -22.00 | -4.00 | 55.00 | 15.00 | 14.00 | 44.00 | 71.00 | 60.00 | 163.00 | -31.00 |
| Total comprehensive income | -25.00 | 34.00 | 67.00 | -72.00 | 14.00 | 54.00 | 79.00 | -93.00 | 78.00 | 19.00 | 167.00 | -38.00 | -28.00 | -76.00 | 154.00 | -100.00 |
| Earnings per share, basic | -0.31 | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 | -1.03 | -0.07 | -0.52 |
| Earnings per share, diluted | -0.31 | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 | -1.03 | -0.07 | -0.52 |
Annual results, as filed
| Line | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue from operations | 7,082.00 | 8,171.00 | 9,151.00 | 8,869.00 |
| Other income | 225.00 | 175.00 | 135.00 | 213.00 |
| Total income | 7,307.00 | 8,347.00 | 9,286.00 | 9,082.00 |
| Cost of materials consumed | 1,682.00 | 1,977.00 | 2,056.00 | 1,996.00 |
| Purchases of stock-in-trade | 952.00 | 1,176.00 | 1,417.00 | 1,431.00 |
| Changes in inventories | 69.00 | -199.00 | -241.00 | -188.00 |
| Employee benefit expense | 1,896.00 | 2,030.00 | 2,307.00 | 2,416.00 |
| Finance costs | 344.00 | 448.00 | 422.00 | 341.00 |
| Depreciation and amortisation | 677.00 | 741.00 | 816.00 | 831.00 |
| Other expenses | 1,854.00 | 1,991.00 | 2,167.00 | 2,293.00 |
| Total expenses | 7,474.00 | 8,164.00 | 8,944.00 | 9,120.00 |
| Profit before exceptional items and tax | -168.00 | 183.00 | 342.00 | -37.00 |
| Exceptional items | -7.00 | -63.00 | 0.00 | -196.00 |
| Profit before tax | -174.00 | 120.00 | 342.00 | -233.00 |
| Current tax | 110.00 | 185.00 | 310.00 | 162.00 |
| Deferred tax | -44.00 | -24.00 | 13.00 | -12.00 |
| Tax expense | 66.00 | 161.00 | 324.00 | 150.00 |
| Profit for the period | -186.00 | 18.00 | 91.00 | -326.00 |
| Profit attributable to owners | — | — | 91.00 | -326.00 |
| Profit attributable to non-controlling interests | — | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 176.00 | 57.00 | 80.00 | 338.00 |
| Total comprehensive income | -11.00 | 75.00 | 171.00 | 12.00 |
| Earnings per share, basic | -1.57 | 0.14 | 0.69 | -2.46 |
| Earnings per share, diluted | -1.57 | 0.14 | 0.68 | -2.46 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 13,671.00 | 14,523.00 | 14,776.00 | 15,312.00 | 15,242.00 | 15,678.00 | 16,189.00 | 17,965.00 |
| Non-current assets | 9,357.00 | 9,687.00 | 9,822.00 | 9,847.00 | 9,860.00 | 9,881.00 | 10,236.00 | 10,773.00 |
| Current assets | 4,313.00 | 4,835.00 | 4,954.00 | 5,464.00 | 5,382.00 | 5,797.00 | 5,953.00 | 7,192.00 |
| Property, plant and equipment | 2,919.00 | 3,363.00 | 3,343.00 | 3,873.00 | 3,930.00 | 4,176.00 | 4,304.00 | 4,451.00 |
| Capital work-in-progress | 966.00 | 853.00 | 989.00 | 566.00 | 621.00 | 489.00 | 567.00 | 799.00 |
| Goodwill | 1,123.00 | 1,108.00 | 1,118.00 | 1,123.00 | 1,130.00 | 1,148.00 | 1,188.00 | 1,257.00 |
| Other intangible assets | 2,842.00 | 2,773.00 | 2,702.00 | 2,617.00 | 2,538.00 | 2,451.00 | 2,462.00 | 2,584.00 |
| Inventories | 1,730.00 | 1,681.00 | 2,060.00 | 2,176.00 | 2,447.00 | 2,313.00 | 2,743.00 | 3,064.00 |
| Trade receivables | 1,389.00 | 1,799.00 | 1,743.00 | 2,134.00 | 1,827.00 | 2,350.00 | 1,985.00 | 2,158.00 |
| Cash and cash equivalents | 396.00 | 196.00 | 252.00 | 357.00 | 270.00 | 369.00 | 499.00 | 1,200.00 |
| Total equity and liabilities | 13,671.00 | 14,523.00 | 14,776.00 | 15,312.00 | 15,242.00 | 15,678.00 | 16,189.00 | 17,965.00 |
| Equity | 6,672.00 | 6,774.00 | 7,758.00 | 7,911.00 | 7,907.00 | 8,125.00 | 8,074.00 | 8,163.00 |
| Equity share capital | 1,193.00 | 1,193.00 | 1,323.00 | 1,323.00 | 1,323.00 | 1,324.00 | 1,326.00 | 1,327.00 |
| Other equity | 5,479.00 | 5,580.00 | 6,435.00 | 6,588.00 | 6,584.00 | 6,801.00 | 6,748.00 | 6,835.00 |
| Total liabilities | 6,999.00 | 7,749.00 | 7,018.00 | 7,400.00 | 7,335.00 | 7,552.00 | 8,116.00 | 9,802.00 |
| Non-current liabilities | 3,811.00 | 3,906.00 | 3,421.00 | 3,031.00 | 2,097.00 | 3,786.00 | 3,956.00 | 5,044.00 |
| Current liabilities | 3,188.00 | 3,843.00 | 3,597.00 | 4,369.00 | 5,237.00 | 3,766.00 | 4,160.00 | 4,758.00 |
| Borrowings, non-current | 3,319.00 | 3,384.00 | 2,861.00 | 2,484.00 | 1,535.00 | 3,214.00 | 3,317.00 | 4,300.00 |
| Borrowings, current | 1,570.00 | 2,121.00 | 1,543.00 | 2,075.00 | 3,108.00 | 1,506.00 | 1,399.00 | 1,196.00 |
| Trade payables | 1,086.00 | 1,193.00 | 1,461.00 | 1,538.00 | 1,336.00 | 1,534.00 | 1,828.00 | 2,479.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 127.00 | 484.00 | 508.00 | 1,005.00 | 185.00 | 892.00 | 890.00 | 1,653.00 |
| Net cash from investing activities | -412.00 | -1,339.00 | -107.00 | -434.00 | -74.00 | -477.00 | -468.00 | -826.00 |
| Net cash from financing activities | 463.00 | 818.00 | -387.00 | -422.00 | -263.00 | -441.00 | -361.00 | -39.00 |
| Purchase of property, plant and equipment | 427.00 | 965.00 | 323.00 | 712.00 | 260.00 | 664.00 | 433.00 | 890.00 |
| Net increase in cash | 185.00 | -32.00 | 20.00 | 166.00 | -158.00 | -37.00 | 38.00 | 794.00 |
| con:CFO.BEFORE_TAX | 252.00 | 673.00 | 560.00 | 1,165.00 | 371.00 | 1,227.00 | 980.00 | 1,863.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | -5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 125.00 | 189.00 | 81.00 | 157.00 | 187.00 | 334.00 | 90.00 | 210.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 34.00 | -4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 1,209.00 | 0.00 | 1,671.00 | 1.00 | 1,872.00 | 0.00 | 992.00 |
| con:INVESTMENTS_SOLD | 0.00 | 834.00 | 0.00 | 1,943.00 | 0.00 | 1,999.00 | 0.00 | 888.00 |
| con:PPE_DISPOSALS | 11.00 | 20.00 | 1.00 | 2.00 | 1.00 | 5.00 | 12.00 | 13.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 20.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-08-22 | 2023-09-27 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 35.02 | 35.02 | 35.02 | 35.02 | 35.02 | 34.95 | 34.95 | 34.95 | 34.95 | 34.86 | 0.35 | 0.35 | 0.35 | 0.35 |
| Domestic institutions | 7.83 | 7.87 | 8.02 | 9.68 | 12.12 | 12.95 | 13.81 | 14.10 | 14.78 | 14.26 | 0.15 | 0.16 | 0.16 | 0.15 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 12.32 | 0.13 | 0.14 | 0.14 | 0.13 |
| Insurance companies | 3.82 | 3.80 | 3.80 | 2.88 | 2.64 | 2.43 | 2.22 | 2.13 | 1.79 | 1.67 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 32.23 | 32.62 | 32.37 | 32.51 | 30.59 | 31.42 | 31.73 | 31.68 | 31.49 | 30.86 | 0.30 | 0.30 | 0.30 | 0.13 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 64.59 | 64.60 | 64.60 | 64.60 | 64.61 | 64.58 | 64.61 | 64.65 | 64.71 | 64.57 | 0.65 | 0.65 | 0.65 | 0.65 |
| Non-institutional | 24.54 | 24.11 | 24.21 | 22.41 | 21.89 | 20.21 | 19.07 | 18.87 | 18.44 | 19.45 | 0.19 | 0.19 | 0.19 | 0.38 |
| Shares outstanding | 1322923098 | 1322948130 | 1322948130 | 1322948130 | 1322948130 | 1325748130 | 1325748130 | 1325748130 | 1325748130 | 1329248130 | 1329248130 | 1329248130 | 1329248130 | 1331348130 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Piramal Pharma Limited | Holding Company | Any other transaction, Interest paid, Purchase of go | 3,052,800,000.00 | 64 |
| Piramal Critical Care, Inc | Subsidiary | Any other transaction, Interest paid, Purchase of go | 2,856,500,000.00 | 57 |
| Piramal Critical Care B.V. | Subsidiary | Any other transaction, Interest received, Purchase o | 1,859,200,000.00 | 24 |
| Piramal Critical Care Limited | Subsidiary | Any other transaction, Interest received, Purchase o | 1,119,100,000.00 | 32 |
| AbbVie Therapeutics India Private Limited | Other Related party | Any other transaction, Sale of goods or services | 994,900,000.00 | 3 |
| Ash Stevens LLC | Subsidiary | Any other transaction, Interest paid, Interest recei | 899,600,000.00 | 45 |
| PEL Pharma Inc. | Subsidiary | Any other transaction, Interest paid, Interest recei | 638,000,000.00 | 23 |
| Piramal Dutch Holdings N.V. | Subsidiary | Any other transaction, Interest paid, Interest recei | 536,000,000.00 | 22 |
| Piramal Healthcare UK Limited | Subsidiary | Any other transaction, Interest received, Purchase o | 420,100,000.00 | 36 |
| Piramal Healthcare Inc. | Fellow Subsidiary | Any other transaction, Interest paid | 380,300,000.00 | 25 |
| Piramal Pharma Solutions Inc. | Subsidiary | Any other transaction, Interest paid, Interest recei | 332,900,000.00 | 45 |
| Piramal Corporate Services Limited | Other Related party | Any other transaction, Purchase of goods or services | 289,600,000.00 | 15 |
| Piramal Healthcare (Canada) Limited | Subsidiary | Any other transaction, Interest paid, Purchase of go | 217,700,000.00 | 32 |
| Staff Provident of Piramal Pharma Limited | Other Related party | Any other transaction | 217,200,000.00 | 1 |
| Yapan Bio Private Limited | Other Related party | Any other transaction, Purchase of goods or services | 204,900,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2023-08-07 | Q1FY24 | PHARMA LIMITED., PIRAMAL PHARMA LIMITED. | Read the call |
| 2023-05-18 | Q4FY23 | Read the call | |
| 2023-02-13 | Q3FY23 | GAGAN, GENERAL, PHARMA LIMITED, PIRAMAL PHARMA LIMITED | Read the call |
| 2022-11-11 | Q2FY23 | OFFICER, PIRAMAL GLOBAL PHARMA, PHARMA LIMITED, PIRAMAL PHARMA LIMITED | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q1FY24 | Q2FY23 | Q3FY23 |
|---|---|---|---|
| Capex | There was a question on the quantum of CAPEX spend in FY'24, Quarter 1? | In all, we've committed about $157 million of growth-oriented CAPEX investments across the various sites, which is expected to be completed over the n… | Our growth CAPEX planned over the next 12 to 18 months are well on track. |
| Capital allocation | And the integration has been done and yes, the current revenues do include a part of Hemmo Pharmaceutical, but remember it was also there part of the … | We have recent acquisition and integration of the Hemmo Pharmaceuticals which makes generic peptide APIs. | In our injectable pain management portfolio, we have scale up challenges at our new CMOs as we transitioned post-acquisition. |
| Costs | We continue to work towards cost optimizations, strategizing procurement and implementing operational expense initiative to mitigate inflationary pres… | Navigating the current inflationary raw material and energy prices is an important challenge for us. | Navigating the current inflationary environment on account of high raw material, energy prices and wage inflation is an important challenge for us in … |
| Debt and cash | Our net debt at the end of Quarter 1 FY'24 is about Rs. | So they can be positioned for success, assuming a positive result from that trial that would be underway, whereas now it seems as they're looking more… | There was a question on what is the current net debt in the books. |
| Demand | We are also seeing healthy demand for our recently expanded facilities offering differentiated capabilities. | November 09, 2022 pipeline or do you continue to believe that you want to grow on the generic space as well in the longer run? | However, the delay in decision-making at the customer's end continues given the macro economic environment and prioritization of R&D pipeline due to l… |
| Guidance | The pricing has also been decided keeping in mind, the regulatory requirements and the general precedence basis guidance by our lead managers to the i… | We expect a similar trend to follow this year as well. | February 09, 2023 over the next 3 to 5 years for us to achieve our margin guidance. |
| Margin | Our EBITDA during the first quarter stood at Rs. | Historically, H2 has always been much stronger than H1, with about 55% of total revenue, and 66% of the EBITDA being booked in H2. | EBITDA margins during the quarter and nine months were 10%, impacted by higher operating margins, including raw material costs, energy prices, wage in… |
| People | And what will be our capacity utilization as of today if I look at the CDMO and anesthesia business? | We spoke about people and attrition, and several measures have been taken to ensure that our vacancies are filled in across multiple sites. | It also included an impact of higher average headcount recruited at our Riverview facility, where expansion has now gone live as I mentioned, and at o… |
| Pricing | Rationale for the rights pricing, it has been out endeavour to keep the pricing fair to enable participation by all shareholders. | It's price increases, where we can in operational excellence as well as cost optimization, and procurement cost optimization as well. | And we're trying to offset that through judicious price increases and working out several cost optimization and operational excellence measures. |
| Revenue growth | Quarter's Performance During the quarter we have registered a year-on-year revenue growth of 18% delivering revenues of Rs. | During the quarter, we registered a revenue growth of 9% delivering revenues of Rs.1,720 crores. | Starting with the performance of the Company in Q3 and nine months FY'23, during the quarter, we registered a year-on-year revenue growth of 11% with … |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-11-11 | Q2FY23 | PIRAMAL PHARMA LIMITED | We expect about 15% revenue growth in the next three to five years. |